PROJECT AEROVIA-CF1
SCF Multi-Target Disease-Modifying Platform for Cystic Fibrosis
Program Code: SCF-CF-S2-0001
Development Objective:
Identify and prioritize therapeutic candidates capable of addressing the major residual disease drivers in Cystic Fibrosis:
- Biofilm persistence
- Neutrophilic inflammation
- ECM destruction
- Fibrotic remodeling
- Oxidative and mitochondrial dysfunction
This stage follows the SCF Ethnobioprospecting and API Discovery workflows.
I. STAGE 2 TARGET SELECTION
Primary Molecular Targets
Target | SCF Role | Priority |
Neutrophil Elastase | Safety Harmonizer | Very High |
CXCR2 | Inflammation Control | Very High |
TGF-β | Anti-Fibrotic | Very High |
Nrf2 | Metabolic Regulator | High |
Biofilm Signaling | Target Modulator | Very High |
II. ETHNOBIOPROSPECTING CAMPAIGN
Using the SCF ethnobioprospecting workflow, the highest-value source libraries for CF residual disease are:
Amazon Basin Library
Several candidates already map to immune regulation, ECM repair, and inflammatory control.
Candidate 1
Uncaria tomentosa (Cat’s Claw)
Source:
Amazon Basin
SCF Database Ranking:
QPS ≈ 820
Primary Bioactives:
- Pentacyclic oxindole alkaloids
Mechanistic Relevance:
CF Target | Activity |
NF-κB | Inhibition |
IL-6 | Suppression |
TNF-α | Suppression |
Oxidative stress | Reduction |
SCF Role:
Safety Harmonizer
Candidate 2
Croton lechleri (Dragon’s Blood)
Source:
Amazon Basin
QPS ≈ 790
Primary Bioactive:
Taspine
Mechanistic Relevance:
CF Target | Activity |
Tissue repair | Promotion |
Epithelial healing | Enhancement |
ECM stabilization | Potential |
SCF Role:
Restorative Agent
Candidate 3
Copaifera spp.
Source:
Amazon Basin
Primary Constituents:
- β-caryophyllene
- Copaiferic acids
Mechanistic Relevance:
CF Target | Activity |
Neutrophilic inflammation | Reduction |
NF-κB | Downregulation |
Airway inflammation | Reduction |
SCF Role:
Safety Harmonizer
Candidate 4
Cordyceps spp.
Source:
Amazon fungal library
Primary Molecule:
Cordycepin
Mechanistic Relevance:
Target | Activity |
Mitochondria | Support |
ATP metabolism | Enhancement |
Cytokine regulation | Modulation |
SCF Role:
Metabolic Regulator
Candidate 5
Himatanthus sucuuba
Source:
Amazon Basin
Primary Constituents:
Iridoids
Mechanistic Relevance:
Target | Activity |
TGF-β | Potential modulation |
Inflammation | Suppression |
Fibrotic signaling | Potential reduction |
SCF Role:
Anti-Fibrotic Candidate
III. CANDIDATE SHORTLIST
Selection Criteria
SCF Principle 1
Targeted Drug Action
SCF Principle 2
Pharmacokinetic Optimization
SCF Principle 3
Metabolic Efficiency
SCF Principle 4
Resistance Prevention
SCF Principle 5
Safety Profile
IV. PRELIMINARY SCF FIBONACCI STACK
F1 — Target Modulator
Candidate:
Biofilm-directed synthetic small molecule (to be discovered)
Role:
Biofilm collapse
F1 — Safety Harmonizer
Candidate:
Uncaria tomentosa alkaloid fraction
Role:
NF-κB suppression
F2 — Metabolic Regulators
Candidate A:
Cordycepin analog
Candidate B:
Nrf2 activator
Role:
Mitochondrial recovery
F3 — Absorption & Delivery Layer
Candidates:
- Liposomal inhalation carrier
- Muco-penetrating nanoparticle
- Dry-powder pulmonary delivery system
F5 — Supportive Layer
Candidates:
- Taspine derivative
- β-caryophyllene derivative
- Iridoid fraction
- Glutathione-support molecule
- ECM stabilization molecule
V. LEAD API DISCOVERY STRATEGY
At this stage we transition from botanical sources to pharmaceutical candidates.
Discovery Track A
Natural Product-Derived Small Molecules
Focus:
- Oxindole alkaloid analogs
- Taspine analogs
- Cordycepin analogs
- Iridoid analogs
Discovery Track B
Novel Synthetic Anti-Biofilm API
Desired Properties:
Requirement | Goal |
Inhalable | Yes |
Anti-biofilm | Yes |
Active against Pseudomonas | Yes |
Active against Burkholderia | Yes |
Synergistic with antibiotics | Yes |
Discovery Track C
Dual-Mechanism Pulmonary Therapy
Targets:
- Neutrophil elastase
- TGF-β
Potential Differentiation:
Single inhaled therapy addressing both inflammation and fibrosis.
VI. STAGE 2 DECISION GATE
Criterion | Status |
Mechanistic Rationale | PASS |
Biomarker Availability | PASS |
Therapeutic Differentiation | PASS |
Translational Feasibility | PASS |
Commercial Opportunity | PASS |
Regulatory Pathway | PASS |
STAGE 2 OUTCOME
ADVANCE TO STAGE 3 — API DISCOVERY & MOLECULAR ENGINEERING
Stage 3 Objectives:
- Select one primary therapeutic architecture.
- Engineer specific API candidates.
- Generate molecular scaffolds.
- Define MoA and MeA.
- Create SCF API Discovery Profiles.
- Perform synergy metric evaluation (TSSM, HSV-F², SV-EQ, MGIS, SPCI).
Recommended Primary Development Path
AEROVIA-CF1A
A first-in-class inhaled anti-biofilm + anti-inflammatory + anti-fibrotic disease-modifying therapeutic platform for cystic fibrosis, designed for use with existing CFTR modulators and for patients with modulator-resistant mutations.
MASTER REGISTRY INDEX
SCF-CF-S2-0001 — Therapeutic Concept Design & Candidate Identification
SCF-API-DP-0001 — API Discovery Profile Framework
SCF-ETHBIO-WF-0001 — Ethnobioprospecting Workflow
SCF-ABMD-DB-0001 — Amazon Basin Medicinal Species Database
SCF-ABMD-SDB-0002 — Amazon Basin Pharmacological Super-Database
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-CF-AEROVIA-0001 — AEROVIA-CF1 Development Program